The New England journal of medicine
-
Randomized Controlled Trial Multicenter Study
The complement inhibitor eculizumab in paroxysmal nocturnal hemoglobinuria.
We tested the safety and efficacy of eculizumab, a humanized monoclonal antibody against terminal complement protein C5 that inhibits terminal complement activation, in patients with paroxysmal nocturnal hemoglobinuria (PNH). ⋯ Eculizumab is an effective therapy for PNH.
-
Randomized Controlled Trial
Transcoronary transplantation of progenitor cells after myocardial infarction.
Pilot studies suggest that intracoronary transplantation of progenitor cells derived from bone marrow (BMC) or circulating blood (CPC) may improve left ventricular function after acute myocardial infarction. The effects of cell transplantation in patients with healed myocardial infarction are unknown. ⋯ Intracoronary infusion of progenitor cells is safe and feasible in patients with healed myocardial infarction. Transplantation of BMC is associated with moderate but significant improvement in the left ventricular ejection fraction after 3 months.
-
Randomized Controlled Trial Multicenter Study
Intracoronary bone marrow-derived progenitor cells in acute myocardial infarction.
Pilot trials suggest that the intracoronary administration of autologous progenitor cells may improve left ventricular function after acute myocardial infarction. ⋯ Intracoronary administration of BMC is associated with improved recovery of left ventricular contractile function in patients with acute myocardial infarction. Large-scale studies are warranted to examine the potential effects of progenitor-cell administration on morbidity and mortality.